| --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------|------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | Agenda | Novartis R&D Day | | | | | | | | | Speakers | | | | | | | | | | Novartis Strategy and Growth Story | | | | | | | | | | Cardiovascular and Renal | | | | | | | | | | Immunology, Hepatology & Dermatology | December 2, 2021 | | | | | | | | | Neuroscience | | | | | | | | | | Oncology | | | | | | | | | | | | | | | ...

Novartis AG (NYSE:NVS) Q3 2021 Earnings Conference Call October 26, 2021 8:00 AM ET Company Participants Vas Narasimhan – Chief Executive Officer Samir Shah – Global Head of Investor Relations Harry Kirsch – Chief Financial Officer Marie France – President of Novartis Pharmaceuticals Susanne Schaffert – President of Novartis Oncology John Tsai – Head of Global Drug Development and Chief Medical Officer Richard Saynor – Chief Executive Officer Karen Hale – Chief Legal Officer Conference Call Participants Gra ...

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References û Q3 2021 Results Investor presentation U NOVARTIS | Reimagining Medicine 1 Investor Relations │ Q3 2021 Results 2 Novartis Q3 Results | October 26, 2021 | Novartis Investor Presentation Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securi ...